AzTrials
AzTrials

Congenital Heart DiseaseNCT00713635

Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome

An observational study of Congenital Heart Disease, run by Columbia University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease. Read more about this study

Who is it for?
Ages Up to 50 years
Conditions the study is for
Congenital Heart Disease
How many people
51 participants
Where
1 siteUnited States
Study dates
Dec 2010to Jan 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 50 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Study subjects will consist of mothers and infants referred to the Morgan Stanley Children's Hospital of New York-Presbyterian for evaluation of complex congenital heart disease consisting of: 1) single ventricle variant, such as hypoplastic left heart (HLHS); 2) Tetralogy of Fallot; 3) Transposition of the Great Vessels, and 4)Lung anomalies. Investigators anticipate that 24 mothers and 24 fetuses/infants will be enrolled during the period of study. This will give the study team a total of 24 women-fetus/infant dyads or 48 subjects total (if one counts the mother and the fetus/infant separately).

Who may be able to join

  • All women who present to Columbia University Medical Center between 18-24 wks gestational age with the following fetal diagnoses will be invited to participate:
  • Hypoplastic Left Heart Syndrome (HLHS)
  • Transposition of the Great Arteries (TGA)
  • Tetralogy of Fallot (TOF)
  • Lung anomalies consisting of either congenital cystic adenomatoid malformations or bronchogenic cysts

Who cannot join

  • Documented fetal chromosomal anomaly
  • Structural brain malformations
  • Evidence of placental insufficiency or Intrauterine growth retardation
  • Documented hydrops fetalis or sustained cardiac arrhythmias
  • Anticipated delivery at an outside hospital

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York

    New York, New York, 10032

Other trials in United States

About this study

Official title: The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome

The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease.

Read the detailed description

Congenital heart disease (CHD) is the most common class of birth defect and is a major cause of infant and child death and morbidity, including neurodevelopmental delay. Children with severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that include learning disability, attention deficit and hyperactivity disorder, behavioral problems and mental retardation. The etiology of neurodevelopmental delay in children with CHD is not fully understood but is thought to be secondary to a combination of pre- and post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD have abnormal blood flow to the brain as measured by Doppler ultrasound. This "centralization" or redirection of blood flow toward vital organs such as the brain has been shown to lead to abnormal brain development in other fetal diseases, such as intrauterine growth restriction. Evidence of the importance of prenatal brain development in the setting of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure and blood flow prior to cardiothoracic surgery. However, to date, associations between abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not been established in the CHD population. Finally, newborns with CHD have been shown to have abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic nervous system, which controls heart rate and blood pressure, may not function properly in infants with CHD.

The study proposes that these changes in blood flows in the fetus with heart disease could be responsible in part for poor brain growth, abnormal brain structure and function and developmental delay in childhood. Investigators will use routine obstetrical ultrasound and fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with CHD. Investigators will use non-invasive fetal monitors to measure fetal heart rate and movement. Investigators will look at brain structure using Magnetic Resonance Imaging (MRI) in the fetus and newborn. Afterbirth, investigators will use non-invasive monitors to measure neonatal heart rate and blood pressure changes in response to a tilt, similar to what is experienced when placing an infant in a car seat. Investigators will use a non-invasive monitor consisting of a sticker applied to the skin to measure the level of oxygen in the brain. Investigators will also measure brain function in the newborn with an electroencephalogram(EEG) that records the electrical signaling between different parts of the brain using a special plastic hat like a swim cap. Regular physical exams with a pediatrician to measure growth and development will take place. A special test designed to detect learning disabilities will also be done when the child is 14 months old. This test will consist of talking with the child, reading stories, and showing the child pictures and colors. There will be no extra blood tests needed and none of the tests pose any risk to the mother, fetus, infant, or child.

The possible benefits to the child and the family will be early identification of any brain abnormality in the newborn period as well as learning disabilities in the toddler which will then allow the child to receive therapies designed to treat these problems. Studies show that early identification and treatment of learning disabilities are important to enhance the potential of the child.

Keywords
Congenital Heart Disease
Medical subject headings
Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00713635
Study groupRoleWhat they receive
1Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
2Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
3Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
4Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Neurodevelopmental scores as measured by the Bayley Scales of Infant Development

    Measured: 18 months of age

Secondary outcomes (5)
  1. Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG

    Measured: Neonatal EEG within 72 hours of birth

  2. Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)

    Measured: Fetal assessment between 18-24 wk GA

  3. Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)

    Measured: Fetal assessment between 28-32 wk GA

  4. Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)

    Measured: Fetal assessment between 34-38 wk GA

  5. Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG

    Measured: Neonatal EEG at 1 month of age

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2008 (estimated)
  2. Study startDec 2010
  3. Primary completionNov 2014
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
51 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00713635
Sponsor's protocol ID
AAAD1879
Status last verified
Jul 2017
First submitted
9 Jul 2008
Last updated
18 Jul 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Congenital Heart Disease, run by Columbia University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Neurodevelopmental scores as measured by the Bayley Scales of Infant Development (time frame: 18 months of age). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in